ChiCTR-TRC-12002745 版本V1.1 版本创建时间2015/12/21 20:10:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR-TRC-12002745 

最近更新日期:

Date of Last Refreshed on:

2015-12-21 20:07:08 

注册时间:

Date of Registration:

2012-12-04 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

针刺合谷穴治疗中枢性面瘫的量效规律及不同刺激量影响经脉体表特异性联系的研究

Public title:

Dose-effect relationship of acupunctrue point Hegu(LI4) on treating central facial paralysis and its influence on the specific skin area

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺合谷穴治疗中枢性面瘫的量效规律及不同刺激量影响经脉体表特异性联系的研究

Scientific title:

Dose-effect relationship of acupunctrue point Hegu(LI4) on treating central facial paralysis and its influence on the specific skin area

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

田光 

研究负责人:

孟智宏 

Applicant:

Tian Guang 

Study leader:

Meng Zhihong 

申请注册联系人电话:

Applicant telephone:

+86 15122337573

研究负责人电话:

Study leader's
telephone:

+86 18722699933

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zghc_2008@163.com

研究负责人电子邮件:

Study leader's E-mail:

yj1988mzh@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

天津市南开区鞍山西道314号天津中医药大学第一附属医院

研究负责人通讯地址:

天津市南开区鞍山西道314号天津中医药大学第一附属医院

Applicant address:

314 Anshan Road West, Nankai District, Tianjin, China

Study leader's address:

314 Anshan Road West, Nankai District, Tianjin, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

天津中医药大学第一附属医院

Applicant's institution:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

TJUTCM-EC20110006

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

天津中医药大学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Tianjin University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

天津中医药大学第一附属医院

Primary sponsor:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

天津市南开区鞍山西道314号

Primary sponsor's address:

314 Anshan Road West, Nankai District, Tianjin, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

国家重点基础研究发展计划

Source(s) of funding:

The National Basic Research Program of China

研究疾病:

中枢性面瘫  

Target disease:

Central facial paralysis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究以传统理论“面口合谷收”为切入点,以针刺合谷穴治疗中枢性面瘫为研究对象,用不同的针刺时间和方向构成不同针刺量针刺合谷穴干预缺血性脑卒中所致中枢性面瘫,以求科学地证实合谷穴治疗中枢性面瘫的疗效,并探寻经脉体表特异性联系及其生物学机制,在此基础上进一步探讨不同针刺量对中枢性面瘫疗效的不同影响,从而阐明穴位主治作用的量效规律,及不同刺激量对经脉体表特异性联系的影响,为提高临床疗效提供科学依据。  

Objectives of Study:

Based on the Traditional Chinese Medicine theory "point Hegu treating diseases in the face and mouth", to explore dose-effect relationship of acupuncture point Hegu on treating central facial paralysis and the route of meridians on the specific body surface and its biological mechanism.We conduct the study of the effects of different needling direction and needling time on treating central facial paralysis caused by stroke. Moreover, this research may further provide full evidence on the therapeutic efficacy of acupuncture hegu to central facial paralysis, and clarifying the dose-effect relationship of meridian points.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)符合脑梗死和中枢性面瘫诊断标准者;(2)自愿接受针刺治疗者;(3)已经签署进入研究知情同意书者;(4)首次发病者;(5)年龄:≥40岁,≤80岁者;(6)病程:发病后30天内者(急性期及恢复早期);(7)NIHSS量表评分:≥5分,≤20分者。

Inclusion criteria

(1) Patients who accord with the diagnosis standard of cerebral infarction and central facial palsy;
(2) Patients who accept the acupuncture treatment voluntarily;
(3) Patients who have signed the informed consent form of clinical trial;
(4) first onset;
(5) Aged 40 to 80;
(6) disease course<30days;
(7) scale score of NIHSS>=5, <=20.

排除标准:

(1)既往有脑卒中史遗有面瘫患者;(2)短暂性脑缺血发作、周围性面瘫、面肌不对称、蛛网膜下腔出血、脑出血手术后患者、采用过溶栓治疗的脑梗塞患者;(3)严重意识障碍者;合并有严重心血管、肝、肾和造血系统等原发性疾病、严重并发症者,如心力衰竭、肾衰竭、癌症等,以及其它对患者生存质量的影响超过中风的疾病或状态;(4)有精神病史、痴呆病史,存在失语等认知功能障碍,不能表述意见者;(5)上肢、面部及腹部患有影响红外热像仪及激光多谱勒血流仪检测的皮肤病或感染发热者;(6)怀疑确有酒精、药物滥用病史,或根据判断,具有降低入组可能性或使入组复杂化的其他病史,如工作环境经常变动,容易造成失访的情况;不能完成基本疗程,依从性可能不好者;(7)正在参加其他临床研究的受试者。

Exclusion criteria:

(1)Patients with preexisting stroke and leave behind facial paralysis;
(2)Patients with transient ischemic attack (TIA), peripheral facial paralysis,asymmetric in face muscle, subarachnoid hemorrhage,postoperation of cerebral hemorrhage,and with the experience of thrombolytic therapy;
(3)Patients with serious disturbance of consciousness, or combined with serious primary disease and complications of cardiovascular, liver, kidney and hematopoietic system, such as heart failure, renal failure, cancer, and other disease or condition which have more affects on patients’s quality of life;
(4)Patients with history of mental illness, dementia, aphasia and cognitive dysfunction, as well as who can not express their opinion ;
(5)Skin disease patients (upper limbs, facial and abdominal ) or infection fever may affect the detection of infrared camera and laser doppler;
(6)Patients are suspected with history of alcohol, drug abuse, or according to the judgmet, they with other medical history, which will make the research complex, such as high frequently change of job which may cause case lose, and who without well compliance;
(7)Patients are simultaneous participating in other clinical research.

研究实施时间:

Study execute time:

From 2012-04-01 00:00:00 To 1990-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2012-07-23 00:00:00 To 1990-01-01 00:00:00

干预措施:

Interventions:

组别:

A组

样本量:

30

Group:

A

Sample size:

干预措施:

直刺5秒

干预措施代码:

Intervention:

direct puncture 5 seconds

Intervention code:

组别:

B组

样本量:

30

Group:

B

Sample size:

干预措施:

斜刺5秒

干预措施代码:

Intervention:

Oblique needling 5 seconds

Intervention code:

组别:

C组

样本量:

30

Group:

C

Sample size:

干预措施:

直刺30秒

干预措施代码:

Intervention:

direct puncture 30 seconds

Intervention code:

组别:

D组

样本量:

30

Group:

D

Sample size:

干预措施:

斜刺30秒

干预措施代码:

Intervention:

Oblique needling 30 seconds

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

天津 

市(区县):

南开 

Country:

China

Province:

Tianjin

City:

NanKai

单位(医院):

天津中医药大学第一附属医院 

单位级别:

三级甲等医院 

Institution
hospital:

The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Level of the institution:

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

面瘫评价量表

指标类型:

主要指标

Outcome:

Facial paralysis evaluation scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

红外热像图

指标类型:

主要指标

Outcome:

Infrared thermal images

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血流量

指标类型:

主要指标

Outcome:

Blood flow

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 40 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由统计员1产生随机数列,将受试对象按照随即数列分组,统计员2负责根据随机数字的序号制作信封并密封,他们均不参加纳入受试对象和以后的试验过程。

Randomization Procedure (please state who generates the random number sequence and by what method):

The statistician 1 produce random sequence and put the subjects according to random sequence groupin

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2012-12-05 00:00:00